Table 10.

Factor VII, antithrombin III, protein C, protein S, and anticardiolipin antibody levels in patients with hepatic artery thrombosis

Sample date
FVII, %
AT III, %
PC, %
PS, %
ACL IgG*
ACL IgM*
ACL IgA*
Normal ranges   —   72-172   95-117   82-175   79-133   10-30   20-30   10-30  
Patient 101-033; test         
   Baseline   12/19/00   15   42   10   52   < 8   < 8   < 5  
   After   12/20/00   19   45   17   47   < 8   < 8   < 5  
   End of study   5/4/01   33   91   33   53   < 8   < 8   < 5  
Patient 101-035†; control         
   After   1/2/01   18   78   104   57   < 8   < 8   < 5  
   End of study   2/9/01   85   37   70   63   < 8   < 8   < 5  
Patient 102-005; control         
   Baseline   5/17/00   20   35   19   28   < 8   22   < 5  
   After   5/18/00   56   58   38   35   < 8   16   < 5  
Patient 102-007; test         
   Baseline   6/11/00   115   101   80   74   < 8   6.7   < 5  
   After   6/11/00   81   72   41   30   < 8   < 5   < 5  
Patient 102-022; control         
   Baseline   9/27/00   16   16   12   31   < 8   5.9   < 5  
   After   9/27/00   96   71   55   46   < 8   5.7   < 5  
Patient 104-013; control         
   Baseline   8/15/00   20   34   25   28   < 8   5.4   < 5  
   After
 		 8/15/00
 		 31
 		 42
 		 35
 		 32
 		 < 8
 		 5.5
 		 < 5
 
Sample date
FVII, %
AT III, %
PC, %
PS, %
ACL IgG*
ACL IgM*
ACL IgA*
Normal ranges   —   72-172   95-117   82-175   79-133   10-30   20-30   10-30  
Patient 101-033; test         
   Baseline   12/19/00   15   42   10   52   < 8   < 8   < 5  
   After   12/20/00   19   45   17   47   < 8   < 8   < 5  
   End of study   5/4/01   33   91   33   53   < 8   < 8   < 5  
Patient 101-035†; control         
   After   1/2/01   18   78   104   57   < 8   < 8   < 5  
   End of study   2/9/01   85   37   70   63   < 8   < 8   < 5  
Patient 102-005; control         
   Baseline   5/17/00   20   35   19   28   < 8   22   < 5  
   After   5/18/00   56   58   38   35   < 8   16   < 5  
Patient 102-007; test         
   Baseline   6/11/00   115   101   80   74   < 8   6.7   < 5  
   After   6/11/00   81   72   41   30   < 8   < 5   < 5  
Patient 102-022; control         
   Baseline   9/27/00   16   16   12   31   < 8   5.9   < 5  
   After   9/27/00   96   71   55   46   < 8   5.7   < 5  
Patient 104-013; control         
   Baseline   8/15/00   20   34   25   28   < 8   5.4   < 5  
   After
 		 8/15/00
 		 31
 		 42
 		 35
 		 32
 		 < 8
 		 5.5
 		 < 5
 

All available reserved plasma samples were assayed after the diagnosis of HAT was reported. Baseline samples were obtained prior to the first study transfusion and after the first transfusion. Additional samples were obtained for 2 patients and end of study.

—indicates not applicable.

*

Ranges reported for ACL (anticardiolipin antibody) IgG, IgM, and IgA are low positive ranges only. ACL assays were performed by the Coagulation Center, Oakland, CA

†

No baseline samples were available for this patient

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal